This year’s most-read articles on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) explored treatment adherence patterns, patient symptom assessment, research on treatment ...

Credit: Bristol Myers Squibb. The approval was based on data from the phase 1/2 TRANSCEND CLL 004 study, which included adults with relapsed or refractory CLL or SLL after progression on a BTKi and ...

CAR T-cell therapy positively benefitted patients with patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Breyanzi (lisocabtagene maraleucel), ...

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are rare in Japan, but a new report affirms the effectiveness of venetoclax (Venclexta) and rituximab (Rituxan) (VenR) in this ...

Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had ...

Please provide your email address to receive an email when new articles are posted on . Researchers reported an ORR of 73.3% with the noncovalent (reversible) BTK inhibitor among patients who ...

Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

Eli Lilly (NYSE:LLY) reported positive Phase 3 data from its BRUIN CLL-321 study of its drug pirtobrutunib, also known as Jaypirca, in the treatment adult patients with chronic lymphocytic leukemia, ...

The US Food and Drug Administration (FDA) has granted accelerated approval to pirtobrutinib (Jaypirca; Eli Lilly and Company) for third-line or later treatment in adults with chronic lymphocytic ...

The US Food and Drug Administration (FDA) granted accelerated approval for zanubrutinib (Brukinsa) to treat patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The ...

Breyanzi, a CAR-T cell therapy, shows promise for relapsed or refractory CLL and SLL, achieving a 47% response rate and 18% complete remission rate. CAR-T therapy modifies patient T cells to target ...